Showing results (241-250 of 463) with videos related to
Sort By:
Pageof 47
Journal of Pharmacological Sciences|April 1, 2014
Adenosine A₂A-receptor antagonist istradefylline enhances the motor response of L-DOPA without worsening dyskinesia in MPTP-treated common marmosetsShin-ichi Uchida, Tomomi Tashiro, Mika Kawai-Uchida, et al.Journal of Neurochemistry|February 9, 2006
Pramipexole protects against MPTP toxicity in non-human primatesMahmoud M Iravani, Claire O Haddon, J Mark Cooper, et al.Psychopharmacology|February 4, 2014
Antidepressant activity of the adenosine A2A receptor antagonist, istradefylline (KW-6002) on learned helplessness in ratsKoji Yamada, Minoru Kobayashi, Shizuo Shiozaki, et al.The Journal of Pharmacology and Experimental Therapeutics|September 9, 2006
In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with\ increased motor disabilityMahmoud M Iravani, Kayhan Tayarani-Binazir, Wing B Chu, et al.Movement Disorders : Official Journal of the Movement Disorder Society|January 29, 2010
Pramipexole combined with levodopa improves motor function but reduces dyskinesia in MPTP-treated common marmosetsKayhan A Tayarani-Binazir, Michael J Jackson, Sarah Rose, et al.Expert Review of Neurotherapeutics|September 16, 2021
Redefining the strategy for the use of COMT inhibitors in Parkinson's disease: the role of opicaponePeter Jenner, José-Francisco Rocha, Joaquim J Ferreira, et al.European Journal of Pharmacology|September 17, 2002
Dopamine reuptake inhibition and failure to evoke dyskinesia in MPTP-treated primatesMatthew J Hansard, Lance A Smith, Michael J Jackson, et al.The Journal of Pharmacology and Experimental Therapeutics|November 20, 2002
Dopamine, but not norepinephrine or serotonin, reuptake inhibition reverses motor deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primatesMatthew J Hansard, Lance A Smith, Michael J Jackson, et al.Movement Disorders : Official Journal of the Movement Disorder Society|January 27, 2004
The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primatesMatthew J Hansard, Lance A Smith, Michael J Jackson, et al.Neurology and Therapy|June 15, 2022
Opicapone as an Add-on to Levodopa in Patients with Parkinson's Disease Without Motor Fluctuations: Rationale and Design of the Phase III, Double-Blind, Randomised, Placebo-Controlled EPSILON TrialJoaquim J Ferreira, Werner Poewe, Olivier Rascol, et al.Pageof 47